Hoth Therapeutics Files 8-K on Security Holder Vote Matters

Ticker: HOTH · Form: 8-K · Filed: 2025-08-05T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: HOTH

TL;DR

HOTH filed an 8-K for a security holder vote - details TBD.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on August 5, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters to be voted on or any associated financial implications.

Why It Matters

This filing indicates that Hoth Therapeutics is engaging its security holders in a voting process, which could pertain to corporate governance or strategic decisions.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new financial risks or material adverse events.

Key Players & Entities

FAQ

What specific matters are being submitted for a vote of Hoth Therapeutics' security holders?

The provided 8-K filing states that it is for the 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters.

When was this 8-K filing submitted to the SEC?

The 8-K filing was submitted on August 5, 2025.

What is Hoth Therapeutics, Inc.'s state of incorporation?

Hoth Therapeutics, Inc. is incorporated in Nevada.

What is the principal executive office address for Hoth Therapeutics, Inc.?

The principal executive offices are located at 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.

What is the SIC code for Hoth Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Hoth Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001213900-25-072068.txt : 20250805 0001213900-25-072068.hdr.sgml : 20250805 20250805160529 ACCESSION NUMBER: 0001213900-25-072068 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250805 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250805 DATE AS OF CHANGE: 20250805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 251184881 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0251896-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-08-05 2025-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported)  August 5, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas ,  5th Floor ,  Suite 5066 New York , NY 10036 (Address of principal executive offices, including ZIP code)   ( 646 )  756-2997 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The  Nasdaq  Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐               Item 5.07 Submission of Matters to a Vote of Security Holders.   On August 5, 2025,  Hoth Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of shareholders (the “Annual Meeting”) for the purpose of holding a shareholder vote on Proposals 1, 2, 3, 4 and 5 set forth below. A total of 5,512,739 shares of the Company’s common stock constituting a quorum, were represented in person or by valid proxies at the Annual Meeting.   At the Annual Meeting, the Company&#8

View on Read The Filing